About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Indian Court Rejects German Drug Giant's Bid With Public Health Interests in Mind

by Kalyani Thivakaran on December 14, 2014 at 6:17 PM
Font : A-A+

 Indian Court Rejects German Drug Giant's Bid With Public Health Interests in Mind

A bid by German drug giant Bayer's, to block a generic version of its blockbuster cancer treatment Nexavar by a local drug maker was rejected by the Indian court on Saturday, which was a move hailed by activists.

The judges rejected an appeal by Bayer on Friday that contested a March 2012 decision by India's patent controller, who had argued the price charged by Bayer for the liver and kidney drug, $5,500-per-person, per month in India was far too costly for most Indians.

Advertisement

Medicins San Frontieres (MSF) on Saturday hailed the ruling, calling it a boost for public health.

The court's decision "demonstrates the independence of the Indian judiciary" in upholding the nation's right to legislate "with public health interests in mind", said Leena Menghaney, South Asia regional head of the medical charity's access campaign.
Advertisement

The court judgement highlighted India's "critical role" in "balancing intellectual property and public health", she said, adding it was clear to the court Bayer had recouped its drug research and development costs in just one year.

The Indian government gave local pharmaceutical house Natco Pharma a licence to produce a copy of life-extending Nexavar at a 97-percent discount to the original price of the Bayer medicine in India.

"We are analysing the (court) order and will determine any future course of action afterwards," Bayer said in a statement, adding the ruling "disappointed" the company.

The ruling could stoke tensions further with Western-based big pharmaceutical companies who say India flouts international patent protection law.

India says it is fully compliant with World Trade Organization patent rules. But the United States has already put India on a "watch-list" of intellectual property violators.

Since India's new right-wing government came to power in May, New Delhi has been under heavy pressure from Washington, prodded by the powerful US pharmaceutical industry, to dilute its strict patent laws.

Indian law stipulates drugs must "satisfy the test of novelty or inventiveness" to win patent protection and does not allow minor tweaks, called "evergreening," to prolong patent life.

Western companies say India's powerhouse generics industry and stringent patent filtering reduce commercial incentives to produce cutting-edge medicines.

India'a Lawyers' Collective, another rights group, said the "momentous" judgement held wide-ranging implications for access to other medicines.

India's vast generics industry is a major supplier of cheap copycat, life-saving drugs to treat diabetes, cancer and other diseases afflicting people locally and globally who cannot afford expensive branded versions.

But health economists say it doesn't matter how far drug prices drop in India for some of the 1.25-billion population, as they are too desperately poor to afford them. India is home to one-third of the world's poorest, according to the World Bank.

Source: AFP
Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Indian Court Rejects German Drug Giant's Bid With Public Health Interests in Mind Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests